NasdaqGM - Delayed Quote USD

Adagene Inc. (ADAG)

Compare
2.0500 +0.0500 (+2.50%)
At close: December 20 at 4:00:00 PM EST
Loading Chart for ADAG
DELL
  • Previous Close 2.0000
  • Open 2.0400
  • Bid --
  • Ask 2.0200 x 100
  • Day's Range 1.8900 - 2.0675
  • 52 Week Range 1.6000 - 4.3800
  • Volume 36,873
  • Avg. Volume 60,812
  • Market Cap (intraday) 90.755M
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.03

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

www.adagene.com

174

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ADAG

View More

Performance Overview: ADAG

Trailing total returns as of 12/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ADAG
6.16%
MSCI WORLD
17.62%

1-Year Return

ADAG
22.02%
MSCI WORLD
18.25%

3-Year Return

ADAG
72.30%
MSCI WORLD
17.09%

5-Year Return

ADAG
89.95%
MSCI WORLD
0.00%

Compare To: ADAG

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ADAG

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    90.31M

  • Enterprise Value

    15.43M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    110.12

  • Price/Book (mrq)

    1.60

  • Enterprise Value/Revenue

    18.91

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.59%

  • Return on Equity (ttm)

    -45.70%

  • Revenue (ttm)

    815.75k

  • Net Income Avi to Common (ttm)

    -31.85M

  • Diluted EPS (ttm)

    -0.7300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    95.67M

  • Total Debt/Equity (mrq)

    36.74%

  • Levered Free Cash Flow (ttm)

    -16.92M

Research Analysis: ADAG

View More

Company Insights: ADAG

Research Reports: ADAG

View More

People Also Watch